Protara Therapeutics TARA
NASDAQ TARA
$2.50 -0.06 (-2.34%)
At close: Oct 21, 2026 · 4:00 PM EDT

Protara Therapeutics (TARA) Current Deferred Revenue (2013)

Updated

Protara Therapeutics (TARA) reported Current Deferred Revenue of $2.95 million for Q4 2013.

Analysis

Protara Therapeutics (TARA) Current Deferred Revenue (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Protara Therapeutics 154.04 Mn -412.46 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 2.95 Mn
API Access

Protara Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=TARA&period=max&api_key=YOUR_API_KEY